Overall, the ablating PANX1 function, pharmacologically or genetically, may constitute a novel multi-pronged therapeutic target for metastatic breast cancer by reverting EMT and decreasing the metastatic ability and invasiveness of breast cancer cells. Here, PANX1 is linked to breast carcinoma.